Lipoprotein(a), Residual Cardiovascular Risk, and the Search for Targeted Therapy

J Am Coll Cardiol. 2024 Apr 23;83(16):1540-1542. doi: 10.1016/j.jacc.2024.03.370. Epub 2024 Mar 25.

Authors

Michael J Blaha¹, Harpreet S Bhatia²

Affiliations

¹ Johns Hopkins Ciccarone Center for the Prevention of Atherosclerotic Cardiovascular Disease, Baltimore, Maryland, USA. Electronic address: mblaha1@jhmi.edu.
² Division of Cardiovascular Medicine, University of California San Diego, La Jolla, California, USA.

PMID: 38537912
DOI: 10.1016/j.jacc.2024.03.370

No abstract available

Keywords: Lp(a); icosapent ethyl; triglycerides.

Publication types

Editorial

MeSH terms

Cardiovascular Diseases*
Heart Disease Risk Factors
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors*
Hypertriglyceridemia*
Lipoprotein(a)
Risk Factors
Triglycerides

Substances

Lipoprotein(a)
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Triglycerides